-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Treatment options for hypertension in high-risk patients
Review
(2649) Views (783) Full article downloads
Authors: Wei-Chuan Tsai
Published Date March 2011
Volume 2011:7 Pages 137 - 141
DOI: http://dx.doi.org/10.2147/VHRM.S11235
Wei-Chuan TsaiDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Abstract: Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.
Keywords: hypertension, high-risk, antihypertensive agent
Readers of this article also read:
Comparative assessment of angiotensin receptor blockers in different clinical settings
Practical recommendations for treatment of hypertension in older patients
Erratum
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Antiplatelet combinations for prevention of atherothrombotic events
Hypertensive nephropathy treatment by heart-protecting musk pill: a study of anti-inflammatory therapy for target organ damage of hypertension
Telmisartan and cardioprotection
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




